• pharma
  • pharmapharma

CONFERENCE

rss_Pharma.jpg...see all
5th Annual Drug Delivery Systems Conference

5th Annual Drug Delivery Systems Conference

Assessing innovations in drug delivery technologies and evaluating business models

10th - 11th February 2010, BSG Conference Centre, London, UK

  1. Background Info
  2. Day 1
  3. Day 2
  4. Partners
  5. Past Papers
Silver Sponsor
  • Gerresheimer Wilden
Associate Sponsors
  • SiTec PharmaBio
  • Hovione
  • Ethypharm
Media Partners
  • PharmiWeb.com
  • BIOTECHNOLOGY EUROPE
  • Future Pharmaceuticals
  • InPharm
  • Pharma Connections Worldwide
Discussion Groups
  • LinkedIn

Background Info

Key Speakers
• Dr. Sven Stegemann, Director, Pfizer
• Dr. Norbert Rasenack, Fellow Inhalation Development, Novartis
• Dr. Jan Möschwitzer, Head Early Pharmaceutical Development, Solvay
• Dr. Oliver Steinbach, Department Head, Philips Research Laboratories
• Dr. Joel Richard, Senior Director, Head of Drug Product Development, Ipsen
• Dr. Duncan F Rogers, Reader, National Heart & Lung Institute, Imperial College London
• Dr. Dejan Djuric, R&D Project Management Excipients, BASF
• Dr. Cheryl Barton, Managing Director, Pharmavision
• Gerry Kamstra, Partner, IP & Life Sciences, Bird and Bird
• Prof. Marc Brown, CSO, MedPharm
• Craig Thomson, Director European Patent Attorney, Murgitroyd & Company
• Dr. Giuseppe Battaglia, Senior Lecturer in Bionanotechnology, University of Sheffield
• Dr. Piet Christiaens, Scientific Director, Toxikon Europe
• Dr Pierandrea Esposito, Associate Director, SiTec PharmaBio

Drug delivery continues to be increasingly important sector in the pharmaceutical industry and has undergone rapid growth in the last few years.

Drug delivery technologies are driving growth of pharmaceutical companies and boosting their revenue by extending the product profitable lifecycle through new formulations, combinations and repositioning.

The predominant focus of this conference will be in advancements being made in the drug delivery technologies and understanding the regulatory and legal issues faced by the them.

By attending this conference, you will hear from leaders with expertise in this area their experience and new concepts. It is not to be missed!

Why Attend?

Key benefits:
• Examine the limitations of leading drug delivery technologies
• Discuss the changing patent landscape for drug delivery
• Understand the latest formulation and regulatory standards
• Gain advice on how do effectively develop and maintain drug delivery deal making in this financial climate
• Assess the future of innovations in the drug formulations technologies in the drug industry
• Network with key industry players from pharma, biotech, device and drug delivery industries

Who should attend?

VPs, Directors, Heads, Managers of:
• Drug Delivery
• Preformulation /Formulation/Stability
• Business Development
• Licensing
• Technology Assessment
• Commercial Development
• Patents
• Lifecycle Management
• Strategic Planning and Development
• Financial Analyst
• Pharmaceutical and Analytical R&D
• Pharmaceutical Science
• Testing
• Product Development
• New Product Planning
• New Technology Evaluation
• Marketing
• Brand Management
• Product Management
• Sales
• Regulatory Affairs

Others:
• Intellectual Property Attorneys
• Venture Capitalists
• Medical Device Companies
• Analysts/Investment Banks
• CROs
• Contract Sales Organisations
• Universities and Government Research
• Testing and manufacturing equipment companies
• Packaging companies 

Day 1

Day One, Wednesday 10th February 2010

09:30 Registration and refreshments

10:00 Opening address from the chair

Dr. Norbert Rasenack
Fellow Inhalation Development
Novartis

10:10 Innovations in trans (dermal) drug delivery
• Issues of drug delivery to the skin
• Past successes and failures (trans) dermal drug delivery
• Innovations in active and passive methods of (trans) dermal drug delivery
• Gene delivery; the final frontier

Dr Marc Brown
Chief Technology Officer
MedPharm

10:50 Drug delivery systems for oncology products
• Cancer market context and expectations
• Key challenges for delivery of oncology products
• Oral chemotherapy: opportunities, challenges and delivery solutions
- Drug permeation and bioavailability enhancement
- Delivery strategies based on nanosystems and lipid-based formulations
• I.v. oncology products: challenges and delivery solutions
- Drug solubilisation
- Modification of biodistribution and toxycology profile of drugs
- Delivery strategies based on nanosystems for small molecules and oligonucleotides
• Subcutaneous oncology products: challenges and delivery solutions
- Sustained-release formulations of peptides
- Perspectives for new s.c. formulations of proteins and mAbs

Dr. Joel Richard
Senior Director, Head of Drug Product Development
Ipsen

11:30 Morning refreshments

11:50 Particle engineering as contributor to a successful pharmaceutical drug product development - challenges, opportunities, trends
• Poorly soluble
• Inhalation delivery systems
• Technologies: opportunities and drawbacks

Dr. Norbert Rasenack
Fellow Inhalation Development
Novartis

12:30 Narcotics - Drug Abuse Alcohol Resistance trends
US and EU narcotic markets
Pharmacological and DDS technologies limiting the abuse
Regulatory issues & differences in EU and US
Existing and future Drug Abuse Alcohol Resistance products

Catherine Herry
Head of Formulation
Ethypharm

13:10 Networking lunch

14:30 Stem cell-based therapeutic delivery: challenges & opportunities
• Ethical debates and funding, immune rejection, cancerous potential and issues surrounding the manufacture of stable, pure cell therapeutics
• Delivery of stem cells for CNS disorders
• Autologous products, derived from a patient’s own tissue, will be the first to reach the market

Dr Cheryl L Barton
Managing Director
Pharmavision

Dr Sara Sleigh
Senior Associate
Pharmavision

15:10 Gatecrashing the cell
• Why it is important to deliver within cells’ cytosol
• Biomimetic strategies for cytosolic delivery
• Delivery of DNA, siRNA, ODN, mRNA and their therapeutic implications
• Delivery of contrast agent and how cytosolic delivery can revolutionise diagnostics
• New therapeutic approaches based on cytosolic delivery

Dr Giuseppe Battaglia
Senior Lecturer in Bionanotechnology
University of Sheffield

15:50 Afternoon refreshments

16:10 Challenges and opportunities in the delivery of small molecules and of biotherapeutics
• Drug delivery role in new drugs development and in lifecycle management
• Trends and changes in delivery of therapeutic biomolecules
• Current issues in small molecules delivery
• New formulation technologies or molecular engineeering?

Dr. Pierandrea Esposito
Associate Director
SiTec PharmaBio

16:50 Future therapeutic targets for respiratory disease
• Incidence and economic burden of asthma and chronic obstructive pulmonary disease (COPD)
• Overview of pathophysiology of asthma and COPD
• Overview of strategies for target identification and novel drug development
• Options for improving existing pharmacotherapy
• Hypothesis-driven novel targets
• Natural products, ‘phytoceuticals’ and non-synthetics
• Assessment of clinical trial progression of new drugs

Dr. Duncan F Rogers
Reader, National Heart & Lung Institute
Imperial College London

17:30 Closing remarks from the chair

17:40 Networking Drinks
Take your discussions further and build new relationships in a relaxed and informal setting 

Day 2

Day Two, Thursday 11th February 2010

09:30 Registration and refreshments

10:00 Opening address from the chair

10:10 Design drug delivery for individual patient populations
• Changing patient population and its relevance for therapy
• Individualisation of drug delivery in development and manufacturing
• Drug delivery for effective medication management
• Drug delivery aligning technology with patient needs

Dr. Sven Stegemann
Director
Pfizer

10:50 Image-guided ultrasound- triggered drug delivery
• Use of drug loaded, temperature (liposomes) and pressure sensitive (microbubbles) systems for ultrasound triggered drug delivery
• Tracking, monitoring and quantifying drug release with ultrasound or MRI through the incorporation of imaging lables in drug carriers
• Formulations and applications for different drug formats: small molecules, biologics, nucleic-acid based therapeutics
• Examples from different disease arease.g. oncology, cardiology, metabolic diseases

Dr. Oliver Steinbach
Department Head
Philips Research Laboratories

11:30 Morning refreshments

11:50 Drug nanocrystals prepared by using different particle size reduction methods
• Overview of particles size reduction technologies used in academia and industry, bottom-up, top-down and combinative processes
• When can API nanonisation helps to improve the bioavailability of poorly soluble compounds
• Aspects to be considered during development: stabilisation, analysis and solidification
• The use of nanonised API at different stages of development
• Case study

Dr. Jan Möschwitzer
Head Early Pharmaceutical Development,
Solvay

12:30 Regulatory Requirements for Biocompatibility Testing of Drug Delivery Devices
• Classification of a Drug Delivery Device: Is the product a Drug or a Device?
• General Considerations regarding Biocompatibility testing
• Typical Biocompatibility Tests to be considered
• Testing/Documentation requirements for the submission of a Medical Device
• Testing/Documentation requirements for the submission of a Medicinal Product/Pharmaceutical Container

Dr. Piet Christiaens
Scientific Director
Toxikon Europe

12:50 Networking lunch

14:10 Drug synthesis and delivery IP due diligence
• Importance of IP protecting manufacturing process and drug delivery technology in late stage investments
• Typical issues around manufacturing process patents
• Typical issues around drug delivery patents
• Subsistence of Supplementary Protection Certificates
• Regulatory Data Protection and Orphan Drug
• Protection in late stage investments

Gerry Kamstra
Partner, IP & Life Sciences
Bird and Bird

14:50 Ensuring collaborations enhance rather than stifle exploitation of new technology
• Problems associated with not addressing ownership of IP early in collaboration
• How the law can help to avoid these problems
• Is there any reason to share IP?
• Examination of collaboration case studies

Craig Thomson
Director European Patent Attorney 
Murgitroyd & Company

15:30 Afternoon refreshments

15:50 Polymeric Solubilizer for Hot Melt Extrusion
• Characterization of a bifunctional polymer which is capable of solubilization and of forming solid solutions with poorly soluble drugs
• Manufacturing of solid solutions
• Applications for polymeric solubilizers
• Solubility and Bioavailability enhancement 

Dr. Dejan Djuric
R&D Project Management Excipients
BASF

16:30 Case studies for the real world: Designing particles for better delivery
• Forcing stubborn particles to dissolve
• Making particles fly, flow and fill
• Crystalline or amorphous: pick your own

Peter Villax
Vice-President
Hovione

17:10 Chair’s closing remarks

17:20 End of Conference 

Partners

Silver Sponsor:

Gerresheimer Wilden
Gerresheimer Wilden is an international development partner and manufacturer for innovative respiratory drug delivery systems. From the first product concept to the delivery of the finished product, we perform all services: Product development, engineering, moldmaking, automation engineering, high volume production in clean-rooms under FDA/GMP conditions, product refinement, assembly, and logistics. Five production sites in Europe , USA and Asia offer local manufacturing capacities. However, all important cross-sectional functions up to the high-volume production start of the product are summarized under the roof of our Technical CompetenceCenters in Germany and USA. This guarantees our customers the very highest product quality and a reduction of time to market. For further information, please visit www.gerresheimer-wilden.com

Associate Sponsors:

SiTec PharmaBio
SiTec PharmaBio is originated from SiTec Consulting, active in Europe since 2000. SiTec PharmaBio develops innovative technologies for drug formulation and delivery to create valuable products. SiTec PharmaBio collaborates with Messer Group for the pharmaceutical development and application of novel, proprietary dense gas fluid technologies, for which it retains the rights for pharmaceutical, biopharma and other life-sciences sectors. SiTec PharmaBio, directly or through its network, also offers services and expertise to pharma and biotech companies, mostly in the areas of early stage drug product development and drug delivery. It covers regulatory documentation and compliance aspects of pharmaceutical R&D, and can provide strategic and technical support to start-up companies.
For further information please visit: www.sitec-pharmabio.com; www.sitec-consult.com

Hovione
When you really care about quality and performance, Hovione is the API partner you choose.
Hovione is an international company with 50 years' experience in Active Pharmaceutical Ingredient development and compliant manufacture. With four FDA inspected sites in the US, China, Ireland and Portugal the company focuses on the most demanding customers, in the most regulated markets. The company offers integrated API, particle design and formulation development and manufacturing. In the inhalation area, Hovione is the only independent company offering such a broad range of services.
Our aim is to do well what is difficult, to provide our customers with products and services they cannot find elsewhere. www.hovione.com

Ethypharm
A world's leading Drug Delivery System Company
Oral route modified release technologies, taste masked and orodispersible tablets, bioavailability enhancement, transmucosal and sublingual technology, nanonization, Drug Abuse deterrence….these are Ethypharm's key expertise for 30 years.
Ethypharm has been developing innovative processes in the area of DDS with a special focus on oral modified release formulation for more than 30 years.
The company provides effective solutions based on its patented technologies to optimize delivery of API* into the human body and offers a complete development service from formulation through to registration and manufacturing.
Ethypharm has thus built strong and lasting relationships with major players in the pharmaceutical industry providing a suitable life cycle management opportunities to existing or new commercial pharmaceutical products.
With 5 production sites (2 FDA) and 4 R&D centers in Europe, North America, India and China, 50 commercial products sold by licensees in more than 70 countries throughout the world, Ethypharm is today a highly international company and one of the world’s leading Drug Delivery company. For further information, please visit www.ethypharm.com

Media Partners:

PharmiWeb.com
PharmiWeb.com is the leading industry-sponsored portal for the pharmaceutical sector. Supported by most of the leading pharmaceutical corporations, PharmiWeb.com provides dynamic real-time news, features, events listings and international jobs to industry professionals across Europe and the US. For further information please email: corporate@pharmiweb.com 

BIOTECHNOLOGY EUROPE
BIOTECHNOLOGY EUROPE is owned by BIOTECHNOLOGY WORLD. It is based and located in Warsaw, Poland. Biotechnology World was founded in 2007 to provide the world’s biotech and pharma information and market to make it universally accessible and useful for scientific and business processes. Its first step to fulfilling that mission was building the BIOTECHNOLOGY EUROPE platform that will allow a quick spread of information in different channels. BIOTECHNOLOGY EUROPE offers companies completed internet public relations, publication and marketing solutions. One of the main goals of BIOTECHNOLOGY EUROPE is to integrate the Biotech and Pharma Sector in Europe to global biotechnology, pharmaceutical and life science activities. For further information please visit www.biotechnology-europe.com 

Future Pharmaceuticals
Future Pharmaceuticals has forged powerful relationships with key industry leaders to provide a platform for successful brand recognition, and for senior decision-makers to have the means to procure and plan implementation strategies based on the topics covered. Positioned to be an authoritative resource within top pharma companies as well as small, specialty, and biotech, Future Pharmaceuticals magazine is geared to create a deep penetration into a highly targeted and responsive audience, bridging the gap between the industries' top issues and the solutions top-tier vendors can provide. For further information, please visit www.futurepharmaus.com 

InPharm
InPharm is the online platform for exclusive pharmaceutical news, comment, contracts, services, jobs and events and is home to InPharmjobs.com, Pharmafile and Pharmafocus. For further information please visit: www.In-Pharm.com 

Pharma Connections Worldwide
Pharma Connections Worldwide® is the leading professional business networking website focused in the Pharmaceutical, Biotechnology and Life Sciences research industry. Our goal is to provide a conduit for delivery of premiere content coupled with the right clientele in order to facilitate business development opportunities among industry professionals responsible for making key decisions in a global marketplace. For further information please visit www.pharmaconnections.com

Enquiries

If you would like more information on the range of sponsorship or exhibition possibilities for visiongain's 5th Annual Drug Delivery Systems 2009 conference, please contact:
Cataldo Tarantini, +44 (0)20 7549 9952
cataldo.tarantini@visiongainglobal.com
Christopher Clegg, +44 (0) 207 336 6143
christopher.clegg@visiongainglobal.com 

Past Papers

Speaker presentations are free to delegates. If you are unable to attend the event, the presentations are published two weeks after the event and are available to purchase.